This challenges the prevailing assumption that deep PSA suppression is a universally positive prognostic marker and emphasizes the continued importance of imaging surveillance and comprehensive risk stratification in the management of metastatic prostate cancer. The gene discussed is KLK3; the disease is metastatic prostate carcinoma.